Display options
Cite
Singh V, Gupta D, Almasan A. Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response. J Cancer Sci Ther. 2015;7(11):347-358doi: 10.4172/1948-5956.1000373.
Singh, V., Gupta, D., & Almasan, A. (2015). Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response. Journal of cancer science & therapy, 7(11), 347-358. https://doi.org/10.4172/1948-5956.1000373
Singh, Vijay, et al. "Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response." Journal of cancer science & therapy vol. 7,11 (2015): 347-358. doi: https://doi.org/10.4172/1948-5956.1000373
Singh V, Gupta D, Almasan A. Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response. J Cancer Sci Ther. 2015 Nov;7(11):347-358. doi: 10.4172/1948-5956.1000373. Epub 2015 Nov 24. PMID: 27413424; PMCID: PMC4939752.
Copy Download .nbib Format: NLM
Share it on

J Cancer Sci Ther. 2015 Nov;7(11):347-358. doi: 10.4172/1948-5956.1000373. Epub 2015 Nov 24.

Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response.

Journal of cancer science & therapy

Vijay Singh, Damodar Gupta, Alexandru Almasan

Affiliations

  1. Metabolic Cell Signaling Research, Institute of Nuclear Medicine & Allied Sciences, Brig SK Mazumdar Marg, Timarpur, Delhi, 110054, India.
  2. Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA; Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.

PMID: 27413424 PMCID: PMC4939752 DOI: 10.4172/1948-5956.1000373

Abstract

Rituximab has been revolutionized and validated CD20 targeting monoclonal antibody. Although, it is widely used for lymphoma therapy and many patients have been benefited. However significant numbers of patients are refractory or developed resistance to current therapies due to low level of CD20 expression and/or availability on cells surface. Thus development of novel anti-CD20 mAbs with great cell killing ability and enhance CD20 levels on cell surface can potentially exploit lymphoma therapy. In this scenario, we are summarizing the recently developed mAbs against CD20 and compounds that have ability to induce CD20 expression at significant level. We also are providing information regarding combination strategy for use of radiation and anti-CD20 mAbs

Keywords: Antibody dependent cellular cytotoxicity; CD20; Complement dependent cytotoxicity; NHL; Programmed Cell Death; Radiation

References

  1. Nat Rev Cancer. 2008 Jun;8(6):473-80 - PubMed
  2. J Immunol. 2006 Jul 1;177(1):362-71 - PubMed
  3. Int J Cancer. 2015 Mar 1;136(5):E359-86 - PubMed
  4. Blood. 2008 Jun 15;111(12 ):5486-95 - PubMed
  5. Br J Haematol. 2012 Feb;156(4):490-8 - PubMed
  6. Semin Hematol. 2010 Apr;47(2):199-210 - PubMed
  7. Hematology Am Soc Hematol Educ Program. 2007;:233-42 - PubMed
  8. Blood. 2010 May 6;115(18):3745-55 - PubMed
  9. Blood. 2013 Aug 15;122(7):1137-43 - PubMed
  10. Indian J Med Paediatr Oncol. 2013 Oct;34(4):292-8 - PubMed
  11. J Clin Oncol. 2001 Jan 15;19(2):389-97 - PubMed
  12. Br J Haematol. 2012 May;157(4):438-45 - PubMed
  13. Blood. 2012 Apr 12;119(15):3523-33 - PubMed
  14. BioDrugs. 2011 Feb 1;25(1):13-25 - PubMed
  15. Blood. 2003 Apr 1;101(7):2507-13 - PubMed
  16. Clin Immunol. 2014 Sep;154(1):37-46 - PubMed
  17. Blood. 2011 Jun 16;117(24):6450-8 - PubMed
  18. Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6248-55 - PubMed
  19. Int J Hematol. 2007 Jul;86(1):49-57 - PubMed
  20. Ann N Y Acad Sci. 2009 Sep;1173:721-8 - PubMed
  21. Blood. 2008 Dec 15;112(13):5180-9 - PubMed
  22. Clin Ther. 2010 Oct;32(11):1911-6 - PubMed
  23. Leuk Lymphoma. 2015 Jan;56(1):42-8 - PubMed
  24. Microsc Res Tech. 2000 Aug 1;50(3):251-7 - PubMed
  25. Eur J Immunol. 2003 Sep;33(9):2398-409 - PubMed
  26. Semin Hematol. 2004 Jul;41(3):234-45 - PubMed
  27. JAMA Oncol. 2015 Jul;1(4):505-27 - PubMed
  28. Blood. 2012 Apr 19;119(16):3698-704 - PubMed
  29. Cancer Biother Radiopharm. 2009 Apr;24(2):185-93 - PubMed
  30. Eur J Immunol. 2011 Aug;41(8):2436-46 - PubMed
  31. Clin Ther. 2008 Oct;30(10):1806-16 - PubMed
  32. Oncologist. 2000;5(5):376-84 - PubMed
  33. J Clin Oncol. 2002 May 15;20(10 ):2453-63 - PubMed
  34. J Clin Oncol. 2005 Mar 10;23(8):1614-5 - PubMed
  35. J Hematol Oncol. 2012 Oct 11;5:64 - PubMed
  36. Oncogene. 2000 Jun 1;19(24):2828-35 - PubMed
  37. Leuk Lymphoma. 2011 Nov;52(11):2097-104 - PubMed
  38. Oncogene. 2007 May 28;26(25):3603-13 - PubMed
  39. Free Radic Biol Med. 2008 Feb 15;44(4):614-23 - PubMed
  40. Blood. 2001 Sep 1;98(5):1326-31 - PubMed
  41. Blood. 2009 Jan 29;113(5):1062-70 - PubMed
  42. MAbs. 2010 Jan-Feb;2(1):14-9 - PubMed
  43. Curr Opin Immunol. 2008 Aug;20(4):444-9 - PubMed
  44. Q J Nucl Med Mol Imaging. 2004 Dec;48(4):305-16 - PubMed
  45. Leuk Lymphoma. 2012 Nov;53(11):2218-27 - PubMed
  46. Clin Cancer Res. 2004 Apr 15;10(8):2868-78 - PubMed
  47. Nat Rev Immunol. 2006 May;6(5):394-403 - PubMed
  48. Blood. 2004 Sep 15;104(6):1793-800 - PubMed
  49. Bratisl Lek Listy. 2005;106(11):348-50 - PubMed
  50. J Clin Oncol. 2005 Feb 1;23 (4):712-9 - PubMed
  51. Biochemistry (Mosc). 2002 Mar;67(3):281-92 - PubMed
  52. Leuk Lymphoma. 2010 Jun;51(6):983-94 - PubMed
  53. Blood. 1990 Apr 1;75(7):1422-5 - PubMed
  54. Eur J Haematol. 2002 Sep;69(3):129-34 - PubMed
  55. Clin Cancer Res. 2009 Apr 15;15(8):2739-46 - PubMed
  56. Blood. 2009 May 14;113(20):4885-93 - PubMed
  57. Blood. 2006 Oct 15;108(8):2648-54 - PubMed
  58. Blood. 2003 Feb 1;101(3):1045-52 - PubMed
  59. Annu Rev Plant Biol. 2005;56:187-220 - PubMed
  60. Clin Adv Hematol Oncol. 2010 May;8(5):1-16 - PubMed
  61. Cytometry. 1997 Nov 1;29(3):242-9 - PubMed
  62. Leuk Lymphoma. 2010 May;51(5):747-55 - PubMed
  63. J Immunol. 1992 Apr 15;148(8):2411-6 - PubMed
  64. Br J Haematol. 2008 Mar;140(6):635-43 - PubMed
  65. Blood. 2010 Jun 24;115(25):5191-201 - PubMed
  66. Int J Oncol. 2011 Jun;38(6):1683-94 - PubMed
  67. Ann Oncol. 2010 Sep;21(9):1870-6 - PubMed
  68. N Engl J Med. 2005 Feb 3;352(5):441-9 - PubMed
  69. J Clin Oncol. 2005 May 20;23(15):3383-9 - PubMed
  70. Mol Cancer Ther. 2011 Jan;10(1):178-85 - PubMed
  71. Blood. 2010 Jun 3;115(22):4393-402 - PubMed
  72. J Clin Oncol. 2004 Jul 1;22(13):2654-61 - PubMed
  73. Semin Hematol. 2010 Apr;47(2):107-14 - PubMed
  74. Blood. 2001 Dec 1;98(12):3383-9 - PubMed
  75. Blood. 2012 May 31;119(22):5126-32 - PubMed
  76. Blood. 2004 Jun 15;103(12 ):4429-31 - PubMed
  77. J Clin Oncol. 2005 Oct 20;23 (30):7565-73 - PubMed
  78. Yale J Biol Med. 2011 Dec;84(4):391-407 - PubMed
  79. J Biol Chem. 2012 Sep 14;287(38):31983-93 - PubMed
  80. J Clin Oncol. 2001 Oct 1;19(19):3918-28 - PubMed
  81. Blood. 2011 Mar 17;117(11):2993-3001 - PubMed
  82. PLoS One. 2014 Nov 03;9(11):e111113 - PubMed
  83. Blood. 2008 Feb 1;111(3):1094-100 - PubMed
  84. Cytokines Cell Mol Ther. 2000 Jun;6(2):81-7 - PubMed
  85. Nat Clin Pract Oncol. 2006 Nov;3(11):594-5 - PubMed
  86. Leuk Res. 2001 Jan;25(1):99-100 - PubMed
  87. J Immunol. 2005 Jun 15;174(12):7859-68 - PubMed
  88. Clin Cancer Res. 2012 Feb 15;18(4):1039-50 - PubMed
  89. Leukemia. 2010 Oct;24(10):1760-8 - PubMed
  90. J Clin Oncol. 2008 Jun 1;26(16):2725-31 - PubMed
  91. Nature. 1975 Aug 7;256(5517):495-7 - PubMed
  92. Curr Pharm Des. 2012;18(23):3399-405 - PubMed
  93. Adv Exp Med Biol. 2008;615:261-98 - PubMed
  94. J Immunol. 2011 Mar 15;186(6):3762-9 - PubMed
  95. Biochem Biophys Res Commun. 2015 Feb 20;457(4):572-7 - PubMed
  96. N Engl J Med. 2002 Jan 24;346(4):235-42 - PubMed
  97. Int J Cancer. 2001 Jun 20;96(3):178-81 - PubMed
  98. Clin Cancer Res. 2004 Dec 1;10 (23 ):7792-8 - PubMed
  99. Curr Opin Investig Drugs. 2009 Jun;10(6):588-96 - PubMed
  100. Blood. 2010 Nov 11;116(19):3705-14 - PubMed
  101. J Clin Oncol. 2009 Jul 10;27(20):3346-53 - PubMed
  102. Blood. 2001 Jan 1;97(1):101-6 - PubMed
  103. Blood. 2003 Nov 15;102(10):3514-20 - PubMed
  104. Leuk Res. 2000 May;24(5):411-5 - PubMed
  105. Haematologica. 2010 Jan;95(1):135-43 - PubMed
  106. Exp Hematol. 2001 Dec;29(12):1410-6 - PubMed
  107. Blood. 2011 Apr 28;117(17):4519-29 - PubMed
  108. J Nucl Med. 2005 Jan;46 Suppl 1:128S-40S - PubMed
  109. J Clin Oncol. 1998 Aug;16(8):2825-33 - PubMed
  110. Lancet Oncol. 2006 May;7(5):379-91 - PubMed
  111. Clin Cancer Res. 2008 Mar 1;14(5):1561-70 - PubMed
  112. PLoS Med. 2008 Mar 25;5(3):e64 - PubMed
  113. J Clin Invest. 1981 Jan;67(1):134-40 - PubMed
  114. J Clin Oncol. 2005 Aug 20;23 (24):5696-704 - PubMed
  115. J Clin Oncol. 2002 Aug 1;20(15):3262-9 - PubMed

Publication Types

Grant support